📇 Rhumatologue · PARIS · (75) · Libéral

MME MARIE-PIERRE LANG

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Praticien-chercheur
13 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PARIS (75)LibéralRPPS 10000505254

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

CABINET DU DR MARIE-PIERRE LANG
56 RUE DE VOUILLE, 75015 PARIS
☎ 0145324076Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

How does occupational physical activity influence health? An umbrella review of 23 health outcomes across 158 observational studies

British journal of sports medicine · 2020

📚 130 citations🎯 RCR 9.96Top 3% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

ObjectivePhysical activity (PA) has substantial benefits across a range of health outcomes. There is uncertainty about the PA-specific health effects, and in particular, the occupational domain. In this umbrella review, we synthesised available evidence on the associations between occupational PA (OPA) and health-related outcomes (including cancer, all-cause mortality and cardiovascular disease). This work informed the development of WHO’s guidelines on PA and sedentary behaviour (2020).DesignUmbrella review of systematic reviews.Data sourceWe performed a literature search in PubMed, Web of Science, Embase, CINAHL and Sportdiscuss from database inception to 2 December 2019.Eligibility criteria for selecting studiesWe included systematic reviews if they contained a quantitative assessment of OPA and its relationship with at least one health-related outcome.ResultsWe summarised the evidence of 17 reviews covering 23 unique health-related outcomes. We graded most evidence as low or very low, or moderate quality. We found health benefits for those engaging in high versus low OPA for multiple cancer outcomes (including colon and prostate), ischaemic stroke, coronary heart disease and mental health (ie, mental well-being and life satisfaction). High OPA was associated with unfavourable health outcomes for all-cause mortality in men, mental ill health (ie, depression and anxiety), osteoarthritis, and sleep quality and duration.ConclusionsWe found favourable associations for most health-related outcomes with high OPA levels, but we also found some evidence for unfavourable associations due to high OPA levels. At this point, there is a need for better quality evidence to provide a unequivocal statement on the health effects of OPA.

Organization, sequence and expression of the HLA-B27 gene: a molecular approach to analyze HLA and disease associations

Immunobiology · 1985

📚 96 citations🎯 RCR 2.04

Lupus-anticoagulant testing at NOAC trough levels

Thrombosis and haemostasis · 2016

📚 40 citations🎯 RCR 1.88

Lire l'abstract Crossref ↓

SummaryNon-vitamin K antagonist oral anticoagulants (NOAC), including rivaroxaban, apixaban or dabigatran, regularly show relevant effects on coagulation tests, making the interpretation of results difficult. The aim of this study was to evaluate possible interferences of NOACs in trough level concentrations in lupus anticoagulant (LA) testing. Citrate plasma specimens of 30 healthy volunteers were spiked with rivaroxaban, apixaban or dabigatran in four plasma concentration levels at or below trough NOAC levels. The NOAC concentration was measured using dedicated surrogate concentration tests and a stepwise diagnostic procedure for LA-testing was applied using screening, mixing and confirmatory testing. Results were compared to NOAC-free specimens. Starting with a plasma concentration of 12.5 ng/ml, dabigatran-spiked specimens showed significant prolongations in the lupus anticoagulant-sensitive activated partial thromboplastin time (aPTT-LA) as well as in the Dilute Russell viper venom time (dRVVT), leading to 43.3% false positives in confirmatory testing in the dRVVT. In contrast, rivaroxaban, beginning with 7.5 ng/ml, exclusively affected dRVVT-based tests. In confirmatory tests, 30.0% of rivaroxaban-spiked specimens showed false positive results. Starting with 18.75 ng/ml apixaban, a significant prolongation of the dRVVT and up to 20.7% false positives in confirmatory tests were found. In contrast to other NOACs tested, apixaban did not present with a dose-dependent increase of the dRVVT ratio. In conclusion, the rate of false positive results in LA-testing is unacceptably high at expected trough levels of NOACs. Even at plasma concentrations below the LLOQ of commercially available surrogate tests, LA testing is best avoided in patients with NOAC therapy.

Cookies & analyse de trafic

MME MARIE-PIERRE LANG

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (13) — classées par pathologie

Transversal5

csDMARDs2

Génétique2

Lupus2

Revue générale2

Activité physique / Rééducation1

Essai clinique1

Partager cette fiche